22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › LIGAND PHARMACEUTICALS INC. › 2024-2025

LIGAND PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and LIGAND PHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 11Reported items
  • 332Asset managers, any item
  • 3,606Fund votes
  • June 6, 2025Meeting date

Results at a glance

Meeting of June 6, 2025: 10 items on LIGAND PHARMACEUTICALS INC.’s Form 8-K, filed June 9, 2025: 8 elected · 2 approved.

Dissent

Notable dissent: 1 director (19.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore LIGAND PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by LIGAND PHARMACEUTICALS INC.

These tallies are LIGAND PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 9, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

LIGAND PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 6, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jason M. Aryeh 13,595,137---- 3,224,8791,363,582 81%Elected—
Elect Director: Todd C. Davis 16,393,716---- 426,3001,363,582 97%Elected—
Elect Director: Nancy R. Gray, Ph.D. 16,470,033---- 349,9831,363,582 98%Elected—
Elect Director: Jason Haas 16,621,292---- 198,7241,363,582 99%Elected—
Elect Director: John W. Kozarich, Ph.D. 15,684,962---- 1,135,0541,363,582 93%Elected—
Elect Director: John L. LaMattina, Ph.D. 15,961,637---- 858,3791,363,582 95%Elected—
Elect Director: Stephen L. Sabba, M.D. 15,789,883---- 1,030,1331,363,582 94%Elected—
Elect Director: Martine Zimmermann, Pharm.D. 16,666,655---- 153,3611,363,582 99.1%Elected—
2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 17,274,429906,8472,322 ---- 95%Approved—
3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers 15,576,2001,183,84359,973 --1,363,582 93%Approved—

Source: LIGAND PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 9, 2025 — read the filing on EDGAR.

How asset managers voted at the LIGAND PHARMACEUTICALS INC. 2024-2025 meeting

332 asset managers disclosed a vote on at least one LIGAND PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of LIGAND PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Jason Haas

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 16,621,292WITHHELD: 198,724

Prior year: 98.5% for (June 14, 2024 meeting) ▲ 0.4 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Jason Haas

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jason Haas”): 16,621,292 for, 198,724 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,267,604 for, 0 abstained.

FOR
FOR: 10,267,604ABSTAIN: 0
Largest asset managers voting on “Election of Directors: Jason Haas” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,348,1400 00For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,2880 00For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle122,0520 00For
Bridge Builder Trust100,5630 00For
Aberdeen93,3030 00For
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Jason M. Aryeh

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD
FOR: 13,595,137WITHHELD: 3,224,879

Prior year: 79.0% for (June 14, 2024 meeting) ▲ 1.8 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Jason M. Aryeh

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jason M. Aryeh”): 13,595,137 for, 3,224,879 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 8,766,116 for, 1,217,155 withheld, 284,333 abstained.

FOR
FOR: 8,766,116ABSTAIN: 284,333WITHHOLD: 1,217,155
Largest asset managers voting on “Election of Directors: Jason M. Aryeh” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,347,0980 51,037For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie00 0689,703Withhold
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,2700 018For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles00 240,6840Abstain
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle00 0122,052Withhold
Bridge Builder Trust100,3080 2550For
Aberdeen00 093,303Withhold
Allspring71,4950 00For
Lincoln Financial26,5180 043,609Mixed
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments00 053,952Withhold
Brighthouse6,1370 044,613Mixed
First Trust49,3480 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: John L. LaMattina, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 9 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 15,961,637WITHHELD: 858,379

Prior year: 96.5% for (June 14, 2024 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: John L. LaMattina, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: John L. LaMattina, Ph.D.”): 15,961,637 for, 858,379 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,266,239 for, 958 withheld, 406 abstained.

FOR
FOR: 10,266,239ABSTAIN: 406WITHHOLD: 958
Largest asset managers voting on “Election of Directors: John L. LaMattina, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,348,1390 10For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,2700 018For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle122,0520 00For
Bridge Builder Trust100,3080 2550For
Aberdeen93,3030 00For
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: John W. Kozarich, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 15,684,962WITHHELD: 1,135,054

Prior year: 90.3% for (June 14, 2024 meeting) ▲ 2.9 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: John W. Kozarich, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: John W. Kozarich, Ph.D.”): 15,684,962 for, 1,135,054 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,170,088 for, 97,109 withheld, 407 abstained.

FOR
FOR: 10,170,088ABSTAIN: 407WITHHOLD: 97,109
Largest asset managers voting on “Election of Directors: John W. Kozarich, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,347,1020 21,037For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,2700 018For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle122,0520 00For
Bridge Builder Trust100,3080 2550For
Aberdeen00 093,303Withhold
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Nancy R. Gray, Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 16,470,033WITHHELD: 349,983

Prior year: 95.8% for (June 14, 2024 meeting) ▲ 2.1 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Nancy R. Gray, Ph.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Nancy R. Gray, Ph.D.”): 16,470,033 for, 349,983 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,264,501 for, 2,848 withheld, 255 abstained.

FOR
FOR: 10,264,501ABSTAIN: 255WITHHOLD: 2,848
Largest asset managers voting on “Election of Directors: Nancy R. Gray, Ph.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,347,1030 01,037For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,2880 00For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle122,0520 00For
Bridge Builder Trust100,3080 2550For
Aberdeen93,3030 00For
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Stephen L. Sabba, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 15,789,883WITHHELD: 1,030,133

Prior year: 95.6% for (June 14, 2024 meeting) ▼ 1.7 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Stephen L. Sabba, M.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Stephen L. Sabba, M.D.”): 15,789,883 for, 1,030,133 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,172,936 for, 94,261 withheld, 407 abstained.

FOR
FOR: 10,172,936ABSTAIN: 407WITHHOLD: 94,261
Largest asset managers voting on “Election of Directors: Stephen L. Sabba, M.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,348,1380 20For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,2700 018For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle122,0520 00For
Bridge Builder Trust100,3080 2550For
Aberdeen00 093,303Withhold
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Todd C. Davis

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 16,393,716WITHHELD: 426,300

Prior year: 98.2% for (June 14, 2024 meeting) ▼ 0.7 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Election of Directors: Todd C. Davis

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Todd C. Davis”): 16,393,716 for, 426,300 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 10,253,686 for, 13,662 withheld, 256 abstained.

FOR
FOR: 10,253,686ABSTAIN: 256WITHHOLD: 13,662
Largest asset managers voting on “Election of Directors: Todd C. Davis” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,348,1390 10For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,2700 018For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle122,0520 00For
Bridge Builder Trust100,3080 2550For
Aberdeen93,3030 00For
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Martine Zimmermann, Pharm.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 16,666,655WITHHELD: 153,361

Prior year: 97.0% for (June 14, 2024 meeting) ▲ 2.0 pts

Details: description as filed, official tally, votes by 78 asset managers

Description as filed by funds: Election of Directors: Martine Zimmermann, Pharm.D.

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Martine Zimmermann, Pharm.D.”): 16,666,655 for, 153,361 withheld, per its Form 8-K filed June 9, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “In accordance with the results below, each nominee was elected to serve as a director of the Company.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 78 asset managers below reported 7,468,394 for.

FOR
FOR: 7,468,394
Largest asset managers voting on “Election of Directors: Martine Zimmermann, Pharm.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,346,5690 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
State Street285,2880 00For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
Columbia Threadneedle122,0520 00For
Aberdeen93,3030 00For
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For
Equitable48,8350 00For
Pacific Life46,9950 00For
AMERICAN BEACON FUNDS46,0130 00For
TIAA43,4430 00For
American Century41,7900 00For
Northern Trust29,9700 00For

Showing the 25 largest of 78 asset managers. All 78 are in the interactive database (link above).

DIRECTOR: M. ZIMMERMANN, PHARM.D.

No official matchDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: votes by 25 asset managers

The 25 asset managers below reported 2,799,210 for, 0 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 2,799,210ABSTAIN: 0
Largest asset managers voting on “DIRECTOR: M. ZIMMERMANN, PHARM.D.” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock1,740,9180 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
Loomis Sayles240,6840 00For
BUFFALO FUNDS135,4820 00For
Bridge Builder Trust100,5630 00For
Calamos56,3440 00For
Jackson National37,4310 00For
AMG FUNDS30,5170 00For
QUANTITATIVE MASTER SERIES LLC18,4070 00For
JPMorgan18,3060 00For
TIFF INVESTMENT PROGRAM10,2420 00For
John Hancock7,4720 00For
Allianz6,7500 00For
PFM Multi-Manager Series Trust3,3130 00For
TIMOTHY PLAN2,9600 00For
Pacer Funds Trust2,5970 00For
Vanguard1,5710 00For
RBB FUND, INC.9780 00For
UNIFIED SERIES TRUST8640 00For
GPS Funds I1610 00For
Innovator ETFs Trust1500 00For
Advisors' Inner Circle Fund III760 00For
WILSHIRE MUTUAL FUNDS INC500 00For
RBB Fund Trust340 00For
NORTHERN LIGHTS FUND TRUST II20 00For

The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 15,576,200AGAINST: 1,183,843

Prior year: 91.9% for (June 14, 2024 meeting) ▲ 1.0 pts

Details: description as filed, official tally, votes by 332 asset managers

Description as filed by funds: Approval, on an advisory basis, of the compensation of the named executive officers

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers”): 15,576,200 for, 1,183,843 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In accordance with the results below, the proposal was approved.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 100 asset managers voting on “Approval, on an advisory basis, of the compensation of the named executive officers” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,347,1021,038 00For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,158130 00For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle0122,052 00Against
Bridge Builder Trust100,308255 00For
Aberdeen093,303 00Against
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco060,753 00Against
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Fund voting reports, all 100 managers: 9,961,097 for, 331,251 against, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 259 asset managers voting on “Approval, on an advisory basis, of the compensation of the named executive officers” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Janus Henderson987,0874,185 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST840,0830 00For
State Street644,9756,761 00For
CONGRESS ASSET MANAGEMENT CO553,5510 00For
Stephens Investment Management Group LLC484,1710 00For
BlackRock435,5297,286 00For
GEODE CAPITAL MANAGEMENT, LLC426,5070 00For
Loomis Sayles382,26528,088 00Mixed
Chicago Capital, LLC342,2980 00For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/319,7670 00For
IMPAX ASSET MANAGEMENT LLC280,2080 00For
ASHFORD CAPITAL MANAGEMENT INC279,0720 00For
VILLERE ST DENIS J & CO LLC262,8700 00For
Northern Trust236,071879 00For
RICE HALL JAMES & ASSOCIATES, LLC236,0060 00For
Ranger Investment Management, L.P.215,3300 00For
Aberdeen0202,487 00Against
FRANKLIN ADVISERS INC182,8530 00For
Charles Schwab172,1100 00For
Private Capital Management, LLC149,3410 00For
Russell Investments117,0200 00For
Granite Investment Partners, LLC109,8390 00For
MELLON INVESTMENTS Corp103,9730 00For
PRINCIPAL GLOBAL INVESTORS103,1860 00For
DRIEHAUS CAPITAL MANAGEMENT LLC98,0560 00For

Institutional-manager reports, all 259 managers: 9,364,710 for, 840,394 against, 268 abstained, 385 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 17,274,429AGAINST: 906,847

Prior year: 95.5% for (June 14, 2024 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: Ratification of Ernst & Young LLP as Ligand's independent registered accounting firm for the fiscal year ending December 31, 2025

LIGAND PHARMACEUTICALS INC.’s own tally for this item (“2. The ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 17,274,429 for, 906,847 against — passed, per its Form 8-K filed June 9, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In accordance with the results below, the selection of Ernst & Young LLP was ratified.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of LIGAND PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (3 managers, 14,091 for).

The 100 asset managers below reported 10,258,135 for, 9,891 against, 0 abstained.

FOR
FOR: 10,258,135AGAINST: 9,891ABSTAIN: 0
Largest asset managers voting on “Ratification of Ernst & Young LLP as Ligand's independent registered accounting firm for the fiscal year endin” at LIGAND PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,348,1391 00For
BlackRock1,740,9180 00For
JANUS INVESTMENT FUND889,8500 00For
Delaware/Macquarie689,7030 00For
Dimensional408,8560 00For
Fidelity405,4010 00For
PROFESSIONALLY MANAGED PORTFOLIOS383,3380 00For
State Street285,27018 00For
MFS281,8790 00For
IMPAX FUNDS SERIES TRUST I280,2080 00For
DWS276,7450 00For
Loomis Sayles240,6840 00For
Franklin Custodian Funds160,0000 00For
Charles Schwab153,8070 00For
BUFFALO FUNDS135,4820 00For
Columbia Threadneedle122,0520 00For
Bridge Builder Trust100,5630 00For
Aberdeen93,3030 00For
Allspring71,4950 00For
Lincoln Financial70,1270 00For
Invesco60,7530 00For
Calamos56,3440 00For
Russell Investments53,9520 00For
Brighthouse50,7500 00For
First Trust49,3480 00For

Showing the 25 largest of 100 asset managers. All 100 are in the interactive database (link above).

Largest LIGAND PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,276,000 shares outstanding at the time of that meeting.

Fund voting reports: top LIGAND PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the named executive officers”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 12.18%
2BlackRock 9.03%
3JANUS INVESTMENT FUND 4.62%
4Delaware/Macquarie 3.58%
5Dimensional 2.12%
6Fidelity 2.10%
7PROFESSIONALLY MANAGED PORTFOLIOS 1.99%
8State Street 1.48%
9MFS 1.46%
10IMPAX FUNDS SERIES TRUST I 1.45%
Institutional-manager reports: top LIGAND PHARMACEUTICALS INC. shareholders by shares voted on “Approval, on an advisory basis, of the compensation of the named executive officers”, 2024-2025
#Asset manager % of shares outstanding
1Janus Henderson 5.14%
2MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 4.36%
3State Street 3.38%
4CONGRESS ASSET MANAGEMENT CO 2.87%
5Stephens Investment Management Group LLC 2.51%
6BlackRock 2.30%
7GEODE CAPITAL MANAGEMENT, LLC 2.21%
8Loomis Sayles 2.13%
9Chicago Capital, LLC 1.78%
10MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 1.66%

Reported LIGAND PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

LIGAND PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Ligand Pharmaceuticals Incorporated8,062,678 41.83%Schedule 13D, filed May 1, 2026
BlackRock2,920,235 15.15%Form 13F, quarter ended March 31, 2025
Vanguard Group2,055,732 10.66%Form 13F, quarter ended March 31, 2025
Vanguard Portfolio Management1,109,154 5.75%Schedule 13G, filed May 1, 2026
JANUS HENDERSON GROUP PLC1,042,378 5.41%Schedule 13G, filed November 14, 2025
Dimensional Fund Advisors744,930 3.86%Form 13F, quarter ended March 31, 2025
State Street727,125 3.77%Form 13F, quarter ended March 31, 2025
Todd C. Davis313,626 1.63%Proxy statement (DEF 14A), proxy filed April 22, 2025
Matthew Korenberg304,480 1.58%Proxy statement (DEF 14A), proxy filed April 22, 2025
Northern Trust293,808 1.52%Form 13F, quarter ended March 31, 2025

Percentages above are of 19,276,000 shares outstanding, as reported by LIGAND PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At LIGAND PHARMACEUTICALS INC.'s shareholder meeting held June 6, 2025, in the 2024-2025 proxy season, 332 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 3,606 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of the named executive officers — LIGAND PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: LIGAND PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 9, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LIGAND PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

LIGAND PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “LIGAND PHARMACEUTICALS (LGND) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ligand-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.